IP Library Granted Patent US 9,023,997
Granted Patent B2
US 9,023,997 · App. 13/574,307 · Granted May 5, 2015

Anti-ILT5 antibodies and ILT5-binding antibody fragments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,023,997
App. No.
13/574,307
Granted
May 5, 2015
Kind
B2
Abstract

Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.

Claims (28)

1. An isolated antibody or an antigen binding fragment thereof that binds human immunoglobulin-like transcript 5 (ILT5) comprising:

a heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO: 4;

a heavy chain complementarity determining region 2 (VH CDR2) comprising the amino acid sequence of SEQ ID NO: 5;

a heavy chain complementarity determining region 3 (VH CDR3) comprising the amino acid sequence of SEQ ID NO: 6;

a light chain complementarity determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO: 7;

a light chain complementarity determining region 2 (VL CDR2) comprising the amino acid sequence of SEQ ID NO: 8; and

a light chain complementarity determining region 3 (VL CDR3) comprising the amino acid sequence of SEQ ID NO: 9.

2. The isolated antibody or fragment of claim 1 , further comprising at least one human framework region.

3. The isolated antibody or fragment of claim 2 , wherein the human framework region is a human heavy chain framework region.

4. The isolated antibody or fragment of claim 3 , comprising one or more human heavy chain framework regions from a heavy chain variable region comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

5. The isolated antibody or fragment of claim 2 , wherein the human framework region is a human light chain framework region.

6. The isolated antibody or fragment of claim 5 , comprising one or more human light chain framework regions from a light chain variable region comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

7. The isolated antibody or fragment of claim 6 , comprising one or more human heavy chain framework regions from a heavy chain variable region comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

8. The isolated antibody or fragment of claim 1 , comprising a heavy chain constant region.

9. The isolated antibody or fragment of claim 8 , wherein the heavy chain constant region is selected from the group consisting of: an IgG1 constant region, an IgG2 constant region, an IgG3 constant region, an IgG4 constant region, an IgA constant region, an IgE constant region, an IgM constant region, and an IgD constant region.

10. The isolated antibody or fragment of claim 8 , wherein the heavy chain constant region is an IgG1 constant region.

11. The isolated antibody or fragment claim 8 , wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 25 or SEQ ID NO: 26.

12. The isolated antibody or fragment of claim 1 , comprising a light chain constant region.

13. The isolated antibody or fragment of claim 12 , wherein the light chain constant region is a kappa light chain constant region.

14. The isolated antibody or fragment of claim 12 , wherein the light chain constant region is a lambda light chain constant region.

15. The isolated antibody or fragment claim 12 , wherein the light chain constant region comprises the amino acid sequence of SEQ ID NO: 27.

16. The isolated antibody or fragment of claim 1 , comprising a light chain comprising the amino acid sequence of SEQ ID NO: 28.

17. The isolated antibody or fragment of claim 16 , further comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32.

18. The isolated antibody or fragment of claim claim 1 , comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32.

19. The isolated antibody or fragment of claim 1 , comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1.

20. The isolated antibody or fragment of claim 1 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

21. The isolated antibody or fragment of claim 1 , comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and further comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

22. An antigen binding fragment of claim 1 , wherein the fragment comprises a Fab fragment, a F(ab′)2 fragment, or a scFv fragment.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2014
From: LIQUIDATING TRUST
To: MERCK SHARP & DOHME CORP.
Reel/Frame 032657/0413 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME AND ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 029100 FRAME 0232. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 25, 2013
From: APOSTOLOU, IRINA; PONATH, PAUL; PONTE, JOE; ROSENZWEIG, MICHAEL
To: LIQUIDATING TRUST
Reel/Frame 031495/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2012
From: APOSTOLOU, IRINA; PONATH, PAUL; PONTE, JOE; ROSENZWEIG, MICHAEL
To: TOLERX, INC.
Reel/Frame 029100/0232 →